People: Cleveland BioLabs Inc (CBLI.PH)
CBLI.PH on Philadelphia Stock Exchange
1.59USD
11:57am EDT
1.59USD
11:57am EDT
Price Change (% chg)
$-0.05 (-3.05%)
$-0.05 (-3.05%)
Prev Close
$1.64
$1.64
Open
$1.59
$1.59
Day's High
$1.59
$1.59
Day's Low
$1.59
$1.59
Volume
100
100
Avg. Vol
--
--
52-wk High
--
--
52-wk Low
--
--
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Bernard Kasten |
66 | 2006 | Independent Chairman of the Board |
Yakov Kogan |
39 | 2012 | Chief Executive Officer, Chief Operating Officer, Secretary, Director |
C. Neil Lyons |
55 | 2011 | Chief Financial Officer |
Andrei Gudkov |
55 | 2003 | Chief Scientific Officer, Director |
Jean Viallet |
55 | 2013 | Chief Development Officer |
Michael Fonstein |
52 | 2013 | President |
James Antal |
61 | 2006 | Independent Director |
Julia Brown |
66 | 2013 | Independent Director |
Paul DiCorleto |
60 | 2004 | Independent Director |
David Hohn |
70 | 2013 | Chairman of the Board |
Anthony Principi |
66 | 2013 | Independent Director |
Randy Saluck |
2013 | Independent Director | |
Rachel Levine |
Director - Corporate Development & Communications |
Biographies
| Name | Description |
|---|---|
Bernard Kasten |
Dr. Bernard L. Kasten, Jr., M.D., has resigned as Independent Chairman of the Board of Cleveland BioLabs, Inc., effective June 2013. Dr. Kasten became a member of board on July 20, 2006 and was appointed Chairman of the Board on August 30, 2006. From 1995 to 2004, Dr. Kasten served at Quest Diagnostics Incorporated where he was Chief Laboratory Officer and most recently Vice President of Medical Affairs of its MedPlus Inc. subsidiary. Dr. Kasten served as a director of SIGA Technologies from May 2003 to December 2006, and as SIGA’s Chief Executive Officer from July 2004 through April 2006. Since April 2007, Dr. Kasten has served as the Chairman of the Board and Chief Executive Officer of GeneLink Inc. Dr. Kasten has served as a director of Enzo BioChem Inc. since 2008. Dr. Kasten is also a director of several privately held companies. Dr. Kasten is a graduate of the Ohio State University College of Medicine. His residency was served at the University of Miami, Florida, and he was awarded fellowships at the National Institutes of Health Clinical Center and National Cancer Institutes, Bethesda, Maryland. He is a diplomat of the American Board of Pathology with certification in anatomic and clinical pathology with sub-specialty certification in Medical Microbiology. |
Yakov Kogan |
Dr. Yakov Kogan Ph.D., MBA, serves as Chief Executive Officer, Chief Operating Officer, Secretary, Director of Cleveland BioLabs, Inc. He has been appointed as Chief Executive Officer of the Company, effcetive June 13, 2012. Dr. Kogan had served as interim Chief Executive Officer since January 2012. Dr. Kogan has served as one of directors since company's inception in June 2003. Dr. Kogan has served as Interim Chief Executive Officer since January 2012 and as Chief Operating Officer since February 2008. Dr. Kogan also served as Executive Vice President of Business Development from inception until February 2008. From 2002 to 2003, he was Director for Business Development at Integrated Genomics where he was responsible for commercial sales and expansion of the company’s capital base. Prior to his tenure in business development, Dr. Kogan worked as a Group Leader/Senior Scientist at Integrated Genomics and ThermoGen, Inc. and as Research Associate at the University of Chicago. Dr. Kogan holds a Ph.D. degree in Molecular Biology from All-Union Research Institute of Genetics and Selection of Industrial Microorganisms (VNIIGenetika) (Moscow, Russia), as well as an MBA degree from the University of Chicago Graduate School of Business. |
C. Neil Lyons |
Mr. C. Neil Lyons, CPA, is Chief Financial Officer of Cleveland BioLabs, Inc., since September 1, 2011. Mr. Lyons has over 30 years of experience related to operations, finance, SEC compliance, complex transactions, strategy, information systems and corporate governance. Prior to joining the Company, from 2005, Mr. Lyons served as Chief Financial Officer and Treasurer of RegeneRx Biopharmaceuticals, Inc., where he led several financial transactions, identified and captured government grant opportunities, directed investor relations activities, developed financial models and implemented investment strategies and employee benefit programs. From 2003 until 2005, Mr. Lyons founded and was the principal of Ironbridge Consulting, a firm that provides executive consulting services relating to financial management, including the implementation of Sarbanes-Oxley Act compliance procedures, to businesses in the Washington D.C. metro area. From 1998 until 2003, Mr. Lyons was the Vice President, Finance, of SkyBridge Limited Partnership, an international satellite broadband start-up affiliated with Alcatel, where he secured amounts of capital and was an active participant in acquisition and joint venture activities. Prior to that, Mr. Lyons served in various positions at Bell Atlantic (now Verizon) and HFS, Inc., a Department of Defense contractor. Mr. Lyons practiced as an auditor at Deloitte and Arthur Young. Mr. Lyons is a certified public accountant and received a Bachelor of Science degree in accounting, magna cum laude, from Florida Southern College. |
Andrei Gudkov |
Dr. Andrei V. Gudkov, Ph.D., D.Sci., is Chief Scientific Officer, Director of Cleveland BioLabs, Inc., since June 2003. Prior to 1990, he worked at The National Cancer Research Center in Moscow, where he led a broad research program focused on virology and cancer drug resistance. In 1990, he reestablished his lab at the University of Illinois at Chicago where he became a tenured faculty member in the Department of Molecular Genetics. His lab concentrated on the development of new functional gene discovery methodologies and the identification of new candidate cancer treatment targets. In 1999, he defined p53 as a determinant of cancer treatment side effects and suggested this protein as a target for therapeutic suppression. In 2001, Dr. Gudkov moved his laboratory to the Lerner Research Institute at the Cleveland Clinic where he became Chairman of the Department of Molecular Biology and Professor of Biochemistry at Case Western Reserve University. In May 2007, Dr. Gudkov joined Roswell Park Cancer Institute, where he is the Senior Vice President of Basic Science and Chairman of the Department of Cell Stress Biology. Dr. Gudkov is a molecular biologist whose research discoveries drive the scientific foundations of the Company. |
Jean Viallet |
Dr. Jean Viallet, M.D., has been appointed as Chief Development Officer of Cleveland BioLabs Inc., effective April 1, 2013. He has over 20 years of experience in the oncology field, initially as a medical oncologist and then as a senior executive at pharmaceutical companies. Most recently, Dr. Viallet established Viallet Oncology Consulting, LLC after serving as the Chief Medical Officer of Precision Therapeutics, Inc. from October 2011 to March 2012. Prior to this, from January 2010 to June 2011, Dr. Viallet guided clinical and preclinical development at Gemin X Pharmaceuticals, Inc., as its Executive Vice President and Chief Medical Officer, culminating in a strategic acquisition by Cephalon, Inc. Prior to serving at Gemin X, which he had joined in November 2002 as its Vice President of Clinical Development and later as its Chief Medical Officer, Dr. Viallet held senior clinical oncology development positions at GlaxoSmithKline plc and Sanofi. Dr. Viallet has also served in several clinical and academic posts at Hospital Notre Dame, Montreal General Hospital, McGill University, and the Universite de Montreal. Dr. Viallet earned a medical degree from the University of Montreal in Montreal, Quebec, Canada. |
Michael Fonstein |
Dr. Michael Fonstein, Ph.D., is President of Cleveland BioLabs, Inc. He has resigned as Director of Cleveland BioLabs, Inc., effective June 2013. Dr. Fonstein has served as President and as one of directors since company's inception in June 2003. Dr. Fonstein also served as Chief Executive Officer from June 2003 until January 24, 2012. Previously, he served as Director of the DNA Sequencing Center at the University of Chicago from its creation in 1994 to 1998, when he left to found Integrated Genomics, Inc. located in Chicago, Illinois. He served as Chief Executive Officer and President of Integrated Genomics from 1997 to 2003. Dr. Fonstein has won several business awards, including the Incubator of the Year Award from the Association of University Related Research Parks. He was also the winner of a coveted KPMG Illinois High Tech Award. |
James Antal |
Mr. James J. Antal, CPA, is an Independent Director of Cleveland BioLabs, Inc., since July 20, 2006. Mr. Antal served as Chief Financial Officer of Experian from 1996 to 2001 and as Chief Investment Officer of Experian from 2001 to 2002. Experian is a global provider of consumer and business credit information, direct marketing information services, and integrated customer relationship management processes. He also served on the Board of Directors of First American Real Estate Solutions, an Experian joint venture with First American Financial Corp. Mr. Antal earned a Bachelor of Science degree in Business Administration with an Accounting major from The Ohio State University in 1973. He became a Certified Public Accountant (Ohio) in 1975. Starting in 2002, Mr. Antal served as an advisor to the board of directors for Plexus Vaccine, Inc., a biotech company, until it was acquired by SIGA Technologies in 2004. In December 2004, he joined the SIGA board of directors, and also currently serves on its audit and corporate governance committees. From May 2004 to August 2005, he was engaged as the Chief Financial Advisor to the Black Mountain Gold Coffee Co. From July 2005 to August 2009, he served on a part-time basis as Chief Financial Officer of Pathway Data Inc., a privately-held company engaged in consumer credit notification and identity theft assistance services. He is Audit Committee Chairman. |
Julia Brown |
Ms. Julia R. Brown has been appointed as Independent Director of Cleveland BioLabs, Inc., effective April 22, 2013. Ms. Brown has held a variety of executive positions over her 40 year career in the pharmaceutical industry. From January 2000 to July 2003, Ms. Brown was Executive Vice President of Amylin Pharmaceuticals, Inc., responsible for commercial operations. She served as Advisor to the CEO until 2008. Prior to joining Amylin, Ms. Brown was Executive Vice President of Dura Pharmaceuticals, Inc. Ms. Brown spent over 25 years with Eli Lilly and Company in progressively more senior roles including Vice President of IVAC Corporation and General Manager of its Vital Signs Division and Vice President of Worldwide Marketing for Hybritech. Ms. Brown is currently a member of the board of directors of Targacept, Inc. and serves as chair of its compensation committee. She is also a member of the board of directors of Biodel Inc. and serves as chair of its compensation committee and is a member of its nominating and governance committee. Previously, she served on the board of directors of Labopharm, Inc. (acquired by Paladin Labs Inc.) and Tanox, Inc. (acquired by Genentech, Inc.). She is a member of the National Association of Corporate Directors and Women Corporate Directors. Ms. Brown is Vice Chair of Corporate Directors Forum. Ms. Brown is Chair Emerita of the board of trustees of the UC San Diego Foundation and is currently a member of the board of CONNECT, an organization that fosters innovation, entrepreneurship and the formation of new companies in southern California. Ms. Brown is a graduate of Louisiana Tech University where she studied microbiology and biochemistry. |
Paul DiCorleto |
Dr. Paul E. DiCorleto, Ph.D., is an Independent Director of Cleveland BioLabs, Inc., since 2004. He is the Chairman of the Lerner Research Institute of the Cleveland Clinic and Chairman of the Department of Molecular Medicine at the Case School of Medicine. Dr. DiCorleto received his undergraduate training in chemistry at Rensselaer Polytechnic Institute and his doctorate in biochemistry from Cornell University. Dr. DiCorleto’s research focuses on the molecular and cellular basis of atherosclerosis. He has been with the Cleveland Clinic since 1981, having served previously as Chairman of the Department of Cell Biology, as an Associate Chief of Staff, and as a member of the Clinic’s Board of Governors and Board of Trustees. On a national level, Dr. DiCorleto has chaired multiple National Institute of Health and American Heart Association review panels, as well as several national conferences on research into heart and vascular disease. He has published over 100 articles in his field and serves on the editorial board of multiple scientific journals. Dr. DiCorleto is a Community Trustee of Cleveland State University and a member of the Association of American Medical College’s Advisory Panel on Research. |
David Hohn |
Mr. David C. Hohn, M.D., has been appointed as Chairman of the Board of Cleveland BioLabs, Inc., effective June 2013. Dr. Hohn is currently a Professor Emeritus and the Executive Director of Health Policy at Roswell Park Cancer Institute in Buffalo, New York, a position in which he has served since April 2007. Dr. Hohn also serves as a senior advisor to the current President of the Roswell Park Cancer Institute. From March 1997 to April 2007, Dr. Hohn served as President and Chief Executive Officer of the Roswell Park Cancer Institute and Principal Investigator on Roswell Park’s National Cancer Institute Cancer Center Support Grant. Prior to joining Roswell Park, Dr, Hohn served as the Vice President for Clinical Affairs at the M.D. Anderson Cancer Center in Houston, Texas. Dr. Hohn is currently active in New York State cancer control initiatives with the American Cancer Society. He is also a former President and a current member of the Executive Committee of the National Comprehensive Cancer Network, an alliance of 21 cancer centers, and he serves as Vice Chair of the New York State Stem Cell Research Board. Dr. Hohn is also a member of the Board of Directors of CUBRC, a non-profit contract research corporation that is a subsidiary of the State University of New York system. Dr. Hohn has previously served as a member of a number of Western New York civic and professional boards, including the Buffalo Niagara Medical Campus, Hauptmann Woodward Medical Institute, Buffalo Niagara Partnership and the Buffalo Philharmonic Orchestra. Dr. Hohn received his undergraduate degree in Chemistry in 1964 at the University of Illinois at Urbana and his Doctorate of Medicine in 1970 from the University of Illinois College of Medicine at Chicago. |
Anthony Principi |
Mr. Anthony J. Principi has been appointed as Independent Director of Cleveland BioLabs, Inc., effective April 22, 2013. Mr. Principi serves as principal of The Principi Group, a consulting firm. From 2005 through 2010, he was Senior Vice President of Government Relations of Pfizer, Inc.. Prior to joining Pfizer, Inc., Mr. Principi served as Secretary of the U.S. Department of Veterans Affairs from 2001 through 2005. In 2005, he served as the Chairman of the Defense 2005 Base Realignment and Closure Commission. Prior to becoming Secretary of the U.S. Department of Veterans Affairs, Mr. Principi was President of QTC Medical Services Inc. from 1999 through 2001 and Senior Vice President of Lockheed Martin IMS from 1995 through 1996. Prior to joining Lockheed Martin IMS, Mr. Principi was Chief Counsel and Staff Director of the U.S. Senate Armed Services Committee from 1993 through 1994, and was Chief Counsel and Staff Director of the U.S. Senate Committee on Veterans’ Affairs from 1984 through 1988. Mr. Principi serves as a director and member of the corporate governance and compensation and evaluation committees of Mutual of Omaha. He is also a member of the board of directors of Engility Holdings, Inc. and is a member of its compensation committee and its nominating/corporate governance committee. Mr. Principi served as Executive Chairman of QTC Management, and was a Director of Perot Systems Corporation. Mr. Principi received a Bachelor of Science from the U.S. Naval Academy and a Juris Doctor from Seton Hall University School of Law. |
Randy Saluck |
Mr. Randy S. Saluck, J.D., MBA, has been appointed as Independent Director of Cleveland BioLabs, Inc., effective May 7, 2013. Mr. Saluck has been the Managing Member of Mortar Rock Capital Management, LLC and the Portfolio Manager of Mortar Rock Capital LP, a value-oriented investment fund, since 2005. From 2002 to 2005, Mr. Saluck was a portfolio manager at the investment fund of Meisenbach Capital, LP and, from 2000 to 2002, Mr. Saluck was a senior analyst at Tyndall Partners, LLC, which invested in value-oriented equities and distressed debt. From 1999 to 2000, Mr. Saluck was an analyst at Highfields Capital Management, LLC, where he was responsible for special situations and risk arbitrage. Prior thereto, Mr. Saluck was an investment banker focused on mergers and acquisitions involving a variety of industries at Salomon Brothers Inc. Before becoming an investment banker, Mr. Saluck was a corporate and securities attorney, working at Cahill Gordon & Reindel LLP and then Tenzer Greenblatt LLP. As an attorney, Mr. Saluck worked with numerous small capitalization companies assisting them in the execution of their financing and strategic plans. He received a Bachelor's degree from the University of Pennsylvania, a Juris Doctor degree from the University of Virginia and an MBA from the Wharton School of the University of Pennsylvania with a concentration in finance and accounting. Mr. Saluck currently serves on the Board of Directors of the Connecticut Region of the Anti-Defamation League. |
Rachel Levine |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Bernard Kasten |
-- |
Yakov Kogan |
1,089,960 |
C. Neil Lyons |
318,181 |
Andrei Gudkov |
952,915 |
Jean Viallet |
-- |
Michael Fonstein |
1,174,760 |
James Antal |
-- |
Julia Brown |
-- |
Paul DiCorleto |
-- |
David Hohn |
-- |
Anthony Principi |
-- |
Randy Saluck |
-- |
Rachel Levine |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Bernard Kasten |
0 | 0 |
Yakov Kogan |
0 | 0 |
C. Neil Lyons |
0 | 0 |
Andrei Gudkov |
0 | 0 |
Jean Viallet |
0 | 0 |
Michael Fonstein |
0 | 0 |
James Antal |
0 | 0 |
Julia Brown |
0 | 0 |
Paul DiCorleto |
0 | 0 |
David Hohn |
0 | 0 |
Anthony Principi |
0 | 0 |
Randy Saluck |
0 | 0 |
Rachel Levine |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
ANTAL JAMES J |
3,700 | $1.56 |
ANTAL JAMES J |
4,300 | $1.35 |
KOGAN YAKOV |
27,482 | $0.00 |
KOGAN YAKOV |
27,482 | $0.00 |
ANTAL JAMES J |
2,316 | $2.60 |
HOHN DAVID C |
1,000 | $1.61 |
FONSTEIN MICHAEL |
8,065 | $0.00 |
GUDKOV ANDREI V |
12,770 | $0.00 |
KOGAN YAKOV |
27,482 | $0.00 |
HOHN DAVID C |
5,584 | $0.00 |
KASTEN BERNARD L JR |
6,342 | $0.00 |
LYONS C NEIL |
20,273 | $0.00 |
KOGAN YAKOV |
15,665 | $0.00 |
ANTAL JAMES J |
3,400 | $1.76 |
HOHN DAVID C |
1,000 | $1.71 |
FONSTEIN MICHAEL |
20,000 | $2.94 |
FONSTEIN MICHAEL |
35,601 | $3.04 |
ANTAL JAMES J |
300 | $3.15 |
FONSTEIN MICHAEL |
44,399 | $3.12 |
ANTAL JAMES J |
300 | $3.14 |
ANTAL JAMES J |
1,300 | $3.16 |
HOHN DAVID C |
1,000 | $2.98 |
ANTAL JAMES J |
100 | $2.76 |
ANTAL JAMES J |
765 | $2.80 |
ANTAL JAMES J |
200 | $2.73 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
